eFfector Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of eFfector Therapeutics with a Buy rating and $5 price target. eFfector is a clinical-stage biotech company focused on developing therapies to address various forms of cancer based on its proprietary technology platform, which involves a class of compounds called selective translation regulator inhibitors, the analyst tells investors in a research note. The firm says the company has a pipeline that contains two clinical compounds in the form of zotatifin and tomivosertib, both of which are poised to deliver near-term data catalysts.